Cryoport Continues Success with Premier Molecular Laboratory Services Provider Cenetron

LAKE FOREST, Calif.--(BUSINESS WIRE)-- Cryoport, Inc. (OTCBB: CYRX) continues to build momentum with the addition of industry leader, Cenetron, based in Austin, Texas. The company is using the Cryoport Express® solution for domestic and international shipments of tissue samples and human serum, and recently finalized an on-site training program including the use of Cryoport’s logistics management platform, the Cryoportal.

Cenetron Diagnostics is a premier provider of molecular laboratory services, providing support for anti-viral and oncology drug development programs, and pharmacogenomics. Founded in 1995, Cenetron has supported pivotal global trials in North and South America, Europe, Africa and the Pacific Rim. Cenetron's client list includes leading pharmaceutical clients in the United States and Europe.

Cenetron’s Vice President of Operations, Brandon Harper stated, “Clients rely on us for the best solutions to their clinical trial needs, and Cryoport Express is the highest standard for shipment integrity, and their one-stop efficiency improves response times and our overall customer relationship. Cryoport provides a level of reliability and transparency through its Cryoportal other logistics providers cannot match.”

“We are extremely pleased that Cenetron has chosen Cryoport for its most important shipping needs,” said Cryoport Chairman Stephen Wasserman. “Cenetron is known as an innovative and responsive clinical trial laboratory, and by using Cryoport Express it can differentiate its offering and improve service to its key life science customers. Central labs must meet a variety of logistics needs based on the type of clinical trial or customer, but in all cases their shipments are of high value. Our continued success in this sector of the healthcare industry reflects the advantages of the Cryoport Express solution, including longer holding time at deep frozen temperatures, state-of-the-art shipment monitoring and tracking, turnkey ordering and billing, and environmental safety.”

About Cryoport

Cryoport provides leading edge cold chain logistics services through the combination of purpose built proprietary technologies and total turnkey management of the entire process. The Cryoport Express® liquid nitrogen dry vapor shipper is validated to maintain a constant -150°C temperature for a 10 plus day dynamic shipment duration, and its Cryoportal™ Logistics Management Platform manages the entire shipment process, including initial order, document preparation, customs clearance, courier management, shipment tracking, issue resolution, and delivery. Cryoport’s total turnkey service management approach offers reliability, cost effectiveness, and convenience, while the use of recyclable and reusable components provides a “green” and environmentally friendly solution. For more information visit www.cryoport.com.

Forward Looking Statements

Statements in this press release which are not purely historical, including statements regarding Cryoport, Inc.’s intentions, hopes, beliefs, expectations, representations, projections, plans or predictions of the future are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. It is important to note that the company's actual results could differ materially from those in any such forward-looking statements. Factors that could cause actual results to differ materially include, but are not limited to, risks and uncertainties associated with the effect of changing economic conditions, trends in the products markets, variations in the company's cash flow, market acceptance risks, and technical development risks. The company’s business could be affected by a number of other factors, including the risk factors listed from time to time in the company's SEC reports including, but not limited to, the annual report on Form 10-K for the year ended March 31, 2012. The company cautions investors not to place undue reliance on the forward-looking statements contained in this press release. Cryoport, Inc. disclaims any obligation, and does not undertake to update or revise any forward-looking statements in this press release.

LHA
Don Markley, 310-691-7100
dmarkley@lhai.com
@LHA_IR_PR

Source: Cryoport, Inc.

Released September 12, 2012